ADHD medications show early promise for perimenopausal brain fog

Preliminary research indicates ADHD medications may improve self-reported executive function in perimenopausal women seeking relief from brain fog. Data presented at The Menopause Society’s annual meeting shows both stimulant and nonstimulant medications significantly improved how women aged 45 to 60 reported their daily functioning, though objective cognitive measures were largely unaffected.

Lisdexamfetamine, sold as Vyvanse, and atomoxetine, sold as Strattera, were assessed in a review of five studies. Participants receiving either drug showed marked reductions in scores on the Brown Attention Deficit Disorder Scale (BADDS) compared to those on a placebo. The improvements were statistically significant.

The review focused on biological women aged 45 to 60 whose last menstrual period was less than ten years ago. It excluded transgender women, those with disordered sleep, surgical menopause, or a history of cancer. An estimated 44% to 60% of perimenopausal women experience cognitive changes like forgetfulness and trouble concentrating.

Expert caution on recommendations

Medical experts stress that current evidence is insufficient to recommend ADHD medications for menopausal brain fog. Stephanie Faubion, medical director at The Menopause Society, said it is too early to recommend these drugs for this use. Larger studies are needed first to establish safety and efficacy.

Jennifer Tat, who led the review, noted the early signs of benefit. "Our review found early signs that ADHD medications may help women feel more on top of their daily lives," Tat said. She suggested a quick screen for ADHD symptoms could be a simple step to help women get appropriate care, while emphasizing it is too early to recommend the medications themselves.

Biological rationale and limitations

The biological rationale centers on the substantial decline and fluctuation in estrogen during menopause. Estrogen mediates catecholaminergic signaling within the prefrontal cortex, an area critical for attention and executive function. Many women notice changes in focus, memory, and organization that resemble ADHD symptoms during this transition.

Neuroimaging data from a subset of women taking lisdexamfetamine provided some support. It showed the drug modulated catecholaminergic pathways, increasing glutamate levels and causing neural activation in brain regions involved in working memory. However, the review has significant limitations. It relied on small sample sizes and subjective, retrospective measures. The minimal or nonsignificant effects on objective cognitive tests, like processing speed and memory recall, mean the study cannot demonstrate that the drugs improve underlying cognition.

Cross-sectional data shows an association between worse ADHD symptoms and greater menopausal symptom burden, but this does not prove causation. The review concludes that ADHD medications may improve subjective executive function by influencing signaling pathways disrupted during menopause, not by enhancing core cognitive abilities. For most women, this brain fog is a temporary condition. "For most women, brain fog at menopause is a temporary condition that does not lead to permanent cognitive changes or dementia," Stephanie Faubion stated. However, it can last long enough to disrupt work, daily routines, and cause significant stress and anxiety. No FDA-approved pharmacological intervention currently exists specifically for this symptom. Further prospective, longitudinal analyses are needed to confirm efficacy and safety.